Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/18342Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Pavlidis, A. N. | en |
| dc.contributor.author | Kalef-Ezra, J. | en |
| dc.contributor.author | Bourantas, L. C. | en |
| dc.contributor.author | Lambrou, A. | en |
| dc.contributor.author | Mavridis, A. | en |
| dc.date.accessioned | 2015-11-24T18:52:01Z | - |
| dc.date.available | 2015-11-24T18:52:01Z | - |
| dc.identifier.issn | 0393-6155 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/18342 | - |
| dc.rights | Default Licence | - |
| dc.subject | Adolescent | en |
| dc.subject | Adult | en |
| dc.subject | Aged | en |
| dc.subject | Aged, 80 and over | en |
| dc.subject | *Blood Sedimentation | en |
| dc.subject | C-Reactive Protein/*analysis | en |
| dc.subject | Female | en |
| dc.subject | Humans | en |
| dc.subject | Leukemia, Lymphocytic, Chronic, B-Cell/*blood/mortality | en |
| dc.subject | Life Tables | en |
| dc.subject | Lymphoma, Non-Hodgkin/*blood/mortality/pathology | en |
| dc.subject | Male | en |
| dc.subject | Middle Aged | en |
| dc.subject | Neoplasm Proteins/*blood | en |
| dc.subject | Prognosis | en |
| dc.subject | Receptors, Interleukin-2/*analysis | en |
| dc.subject | Survival Analysis | en |
| dc.subject | Tumor Markers, Biological/*blood | en |
| dc.subject | beta 2-Microglobulin/*analysis | en |
| dc.title | Serum tumor markers in non-Hodgkin's lymphomas and chronic lymphocytic leukemia | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/8496627 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 1993 | - |
| heal.abstract | The levels of soluble interleukin-2 receptors (sIL-2R), beta-2 microglobulin (beta-2M), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were measured in the serum of 50 previously untreated patients with non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL) as well as in 25 age and sex-matched normal controls. Compared to normal controls, mean serum levels of sIL-2R and beta-2M were significantly increased in both NHL and CLL (p < 0.001) while the increase in ESR and CRP was less marked (p < 0.01 and p < 0.05, respectively). Comparison of these tumor markers with histologic grading showed statistically significant differences only for CRP between low, intermediate and high-grade lymphomas (p < 0.001 and p < 0.05). More advanced stages exhibited higher mean values of all serum markers than early stages (p < 0.001 for sIL-2R, beta-2M and ESR and p < 0.05 for CRP). An association with the presence of b-symptoms was observed only for sIL-2R (p < 0.05). In addition, sIL-2R as well as beta-2M were able to predict time to progression in patients with diffuse large-cell lymphomas. We conclude that of the four tumor markers tested sIL-2R and beta-2M more frequently showed increased serum levels and were associated with clinical stage and/or presence of b-symptoms. Both sIL-2R and beta-2M were also found to have prognostic significance for survival. | en |
| heal.journalName | Int J Biol Markers | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
